Automating and scaling adherent cell manufacturing for clinical and commercial success

Thursday 06:30 PST / 09:30 EST / 14:30 GMT / 15:30 CET

Sponsor

Automating and scaling adherent cell manufacturing for clinical and commercial success

Explore how early automation decisions can streamline adherent cell therapy workflows, reduce costs, and accelerate progress to the clinic.

Hear two expert perspectives:

A journey from academia to a spin-off biotech company mastering MSC manufacturing

Mandana Haack-Sørensen, Director of Manufacturing, Cell to Cure

Lessons from advancing MSC therapies from early development to GMP-compliant clinical manufacturing, including overcoming CMC hurdles and building scalable processes while highlighting therapeutic applications for indications such as heart failure and autoimmune disease.

Automating to scale up & out adherent cell manufacturing in hollow-fiber bioreactors

Nathan Frank, Senior Research Scientist, Terumo Blood and Cell Technologies

Practical real-world guidance on implementing closed-system automation strategies for robust expansion.

Together, the speakers will share best practices for manufacturing adherent cells – including MSCs, iPSCs, and HEK293T cells.

Attend this webinar to:

Understand how early automation choices can save years in development timelines and accelerate clinical and commercial readiness
Gain practical guidance on overcoming CMC and scaling challenges while maintaining product quality and controlling costs
Learn process-focused strategies – such as direct loading of whole bone marrow into a closed automated system without any pre-processing

Nathan Frank

Senior Research Scientist at Terumo Blood and Cell Technologies

Nate has more than a decade of experience optimizing parameters for cell and gene therapy production and scale-up. He has specialized expertise in hollow fiber bioreactor process development for a range of cell types aimed at various applications in regenerative medicine and immunotherapy. He is a two-time National Science Foundation fellow and has a passion for teaching and communicating science to a wide range of audiences from established professionals to middle and high school students who are just beginning their scientific journey.

Mandana Haack-Sørensen

Director of Manufacturing at Cell to Cure

Mandana Haack-Sørensen, MSc, PhD is a leading expert in stem cell manufacturing and translational research with more than two decades of experience in cell therapy innovation. As Director of Manufacturing at Cell to Cure, she oversees the compliant production of advanced cell-based therapies for national and international clinical trials. Her expertise spans functional cell biology, regenerative medicine, quality assurance, quality control, and the development of both manual and automated cell expansion platforms. Mandana previously held leadership roles at the Cardiology Stem Cell Centre at Rigshospitalet, where she managed stem cell production, storage, and distribution. She holds a doctorate in Health Sciences from the University of Copenhagen and a master’s degree from the University of Southern Denmark. As a published scientist with over 50 peer-reviewed articles, she is also a co-inventor on a patent for adipose-derived stem cell therapy and co-founder of Cell to Cure, a company born out of the Capital Region of Denmark.

You have registered for this webinar